SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit

Core Viewpoint - The Gross Law Firm is notifying shareholders of Soleno Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and safety concerns related to the company's product DCCR [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 26, 2025, to November 4, 2025, Soleno Therapeutics issued materially false and misleading statements regarding the safety of DCCR [3]. - It is claimed that the Phase 3 clinical trial program for DCCR downplayed and concealed significant safety concerns, particularly issues related to excess fluid retention in participants [3]. - As a result of these alleged misrepresentations, the safety risks associated with DCCR for treating hyperphagia in individuals with PWS were materially greater than disclosed [3]. Group 2: Commercial Viability - The allegations suggest that DCCR has materially lower commercial viability due to undisclosed risks, including potential adverse events post-launch, patient discontinuation rates, and prescriber reluctance [3]. - The complaint indicates that these risks could lead to adverse regulatory actions and reputational damage for the company [3]. Group 3: Next Steps for Shareholders - Shareholders who purchased shares of SLNO during the specified class period are encouraged to register for the class action by May 5, 2026, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].